96 related articles for article (PubMed ID: 1531404)
1. Suramin-induced skin reactions.
O'Donnell BP; Dawson NA; Weiss RB; Myers CE; James WD
Arch Dermatol; 1992 Jan; 128(1):75-9. PubMed ID: 1531404
[TBL] [Abstract][Full Text] [Related]
2. [Cutaneous drug reaction caused by suramin in 4 patients with metastatic prostate cancer].
Wichterich K; Tebbe B; Handke A; Dieckmann KP; Gollnick H
Hautarzt; 1994 Feb; 45(2):84-7. PubMed ID: 8150636
[TBL] [Abstract][Full Text] [Related]
3. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
Vogelzang NJ; Karrison T; Stadler WM; Garcia J; Cohn H; Kugler J; Troeger T; Giannone L; Arrieta R; Ratain MJ; Vokes EE
Cancer; 2004 Jan; 100(1):65-71. PubMed ID: 14692025
[TBL] [Abstract][Full Text] [Related]
4. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
Ahles TA; Herndon JE; Small EJ; Vogelzang NJ; Kornblith AB; Ratain MJ; Stadler W; Palchak D; Marshall ME; Wilding G; Petrylak D; Holland JC;
Cancer; 2004 Nov; 101(10):2202-8. PubMed ID: 15484217
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
Bowden CJ; Figg WD; Dawson NA; Sartor O; Bitton RJ; Weinberger MS; Headlee D; Reed E; Myers CE; Cooper MR
Cancer Chemother Pharmacol; 1996; 39(1-2):1-8. PubMed ID: 8995493
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
[TBL] [Abstract][Full Text] [Related]
7. Severe thrombocytopenia in patients treated with suramin: evidence for an immune mechanism in one.
Tisdale JF; Figg WD; Reed E; McCall NA; Alkins BR; Horne MK
Am J Hematol; 1996 Feb; 51(2):152-7. PubMed ID: 8579057
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous eruptions from suramin. A clinical and histopathologic study of 60 patients.
Lowitt MH; Eisenberger M; Sina B; Kao GF
Arch Dermatol; 1995 Oct; 131(10):1147-53. PubMed ID: 7574831
[TBL] [Abstract][Full Text] [Related]
9. Suramin keratosis: a unique skin eruption in a patient receiving suramin for metastatic prostate cancer.
Kenner JR; Sperling LC; Waselenko J; Dawson N; Sau P; Moul JW
J Urol; 1997 Dec; 158(6):2245-6. PubMed ID: 9366363
[No Abstract] [Full Text] [Related]
10. Acute renal toxicity associated with suramin in the treatment of prostate cancer.
Figg WD; Cooper MR; Thibault A; Headlee D; Humphrey J; Bergan RC; Reed E; Sartor O
Cancer; 1994 Sep; 74(5):1612-4. PubMed ID: 8062193
[TBL] [Abstract][Full Text] [Related]
11. Postoperative complications in patients receiving suramin therapy.
Cole DJ; Ettinghausen SE; Pass HI; Danforth DN; Linehan MW; Myers CW; Cooper MR; Sindelar WF
Surgery; 1994 Jul; 116(1):90-5. PubMed ID: 8023275
[TBL] [Abstract][Full Text] [Related]
12. Erythema multiforme induced by suramin.
Katz SK; Medenica MM; Kobayashi K; Vogelzang NJ; Soltani K
J Am Acad Dermatol; 1995 Feb; 32(2 Pt 1):292-3. PubMed ID: 7829723
[No Abstract] [Full Text] [Related]
13. Anaphylactoid reaction with suramin.
Thibault A; Figg WD; Cooper MR; Prindiville SA; Sartor AO; Headlee DJ; Myers CE
Pharmacotherapy; 1993; 13(6):656-7. PubMed ID: 8302692
[TBL] [Abstract][Full Text] [Related]
14. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent.
Jaber SH; Cowen EW; Haworth LR; Booher SL; Berman DM; Rosenberg SA; Hwang ST
Arch Dermatol; 2006 Feb; 142(2):166-72. PubMed ID: 16490844
[TBL] [Abstract][Full Text] [Related]
15. Suramin in adrenocortical cancer: limited efficacy and serious toxicity.
Arlt W; Reincke M; Siekmann L; Winkelmann W; Allolio B
Clin Endocrinol (Oxf); 1994 Sep; 41(3):299-307. PubMed ID: 7955436
[TBL] [Abstract][Full Text] [Related]
16. Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation.
LaRocca RV; Cooper MR; Uhrich M; Danesi R; Walther MM; Linehan WM; Myers CE
Urol Clin North Am; 1991 Feb; 18(1):123-9. PubMed ID: 1992566
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer.
Tu SM; Pagliaro LC; Banks ME; Amato RJ; Millikan RE; Bugazia NA; Madden T; Newman RA; Logothetis CJ
Clin Cancer Res; 1998 May; 4(5):1193-201. PubMed ID: 9607577
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate.
Scheinfeld N
J Drugs Dermatol; 2006 Mar; 5(3):228-31. PubMed ID: 16573254
[TBL] [Abstract][Full Text] [Related]
19. Eruptive disseminated superficial porokeratosis with rapid resolution: a drug-induced phenomenon?
Goulding JM; Teoh JK; Carr RA; Humphreys F; Gee BC
Clin Exp Dermatol; 2009 Dec; 34(8):895-7. PubMed ID: 19508573
[TBL] [Abstract][Full Text] [Related]
20. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]